Key result
Pretreatment with quinidine did not significantly enhance the respiratory depressive or miotic effects of morphine compared to placebo in healthy volunteers.
Why the study?
Does quinidine pretreatment enhance the central nervous effects of morphine in healthy volunteers?
RCT (n=12)
Double-blind
2-way crossover
Does quinidine pretreatment enhance the central nervous effects of morphine in healthy volunteers?
Pretreatment with the P-glycoprotein inhibitor quinidine does not enhance the central nervous system effects or alter the pharmacokinetics of intravenous morphine in healthy volunteers.
Answers are grounded in this paper and cite their sources.
Quinidine does not potentiate morphine CNS effects; challenges P-glycoprotein inhibition as a modulator of opioid central actions.
AIM: Our objective was to evaluate whether P-glycoprotein inhibition after quinidine pretreatment results in modified central nervous effects of morphine. METHODS: Twelve healthy volunteers received 7.5 mg morphine as an intravenous infusion over a 3-hour period. In a randomized, double-blind, 2-way crossover fashion, subjects received either 800 mg quinidine or placebo 1 hour before the start of morphine administration. The miotic and respiratory depressive effects of morphine were assessed by means of pupillometry and the respiratory response to carbon dioxide rebreathing, respectively. Quinidine effects were assessed by electrocardiogram recordings. Plasma concentrations of morphine and its glucuronide metabolites were measured throughout the observation period of 5 hours. RESULTS: Morphine significantly reduced both the respiratory response to carbon dioxide and the pupil diameter. Throughout the observation period, quinidine had significant effects on the corrected QT interval (QTc increase of >60 milliseconds), indicating clinically relevant quinidine action. However, quinidine pretreatment did not enhance the respiratory depressive effects of morphine, nor did it alter the miotic effects of morphine to a statistically significant or clinically relevant extent. Plasma concentrations of morphine and its glucuronides were not significantly changed by quinidine pretreatment. CONCLUSIONS: Whereas morphine clearly produced miosis and respiratory depression, pretreatment with quinidine as an inhibitor of P-glycoprotein did not result in an enhancement of central nervous opioid effects in healthy volunteers.
No takes yet. Share an insight, caveat, or question.
Carsten Skarke (2003) conducted an RCT in Healthy volunteers (n=12). Quinidine vs. Placebo was evaluated on Respiratory response to carbon dioxide rebreathing and pupil diameter. Pretreatment with quinidine did not significantly enhance the respiratory depressive or miotic effects of morphine compared to placebo in healthy volunteers.
Synapse has enriched 10 related papers. Consider them for comparative context: